Market Size of Europe Epigenetics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 14.50 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Epigenetics Market Analysis
The European epigenetics market is expected to register a CAGR of nearly 14.5% over the forecast period. Factors that are responsible for the growth of this market include the increasing incidence and prevalence of cancer, the increasing funding for R&D in healthcare, and rising epigenetic applications in non-oncology diseases.
The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.
Europe Epigenetics Industry Segmentation
Epigenetics is defined as the study of changes in gene expression, which are caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions. This report forecasts revenue growth at country levels and provides an analysis of industry trends in each of the sub - segments from 2017 to 2025. For the purpose of this study, Mordor Intelligence has segmented the Europe epigenetics market report on the basis of product, technology, application, and country.
Europe Epigenetics Market Size Summary
The European epigenetics market is experiencing significant growth, driven by the increasing incidence of cancer and the rising applications of epigenetics in non-oncology diseases. The market is benefiting from enhanced funding for research and development in healthcare, which is facilitating advancements in the field. Epigenetics plays a crucial role in understanding gene expression changes, particularly in cancer diagnosis, which is vital given the high prevalence of cancer in Europe. This growing demand for epigenetic applications in cancer research is expected to propel market expansion, despite challenges such as the high cost of instruments.
The market landscape in Europe is moderately competitive, with several key players holding substantial market shares. Companies like Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc. are prominent in the industry, contributing to its dynamic nature. The reduction in gene sequencing costs has enabled extensive research, allowing for the comparison of DNA from diseased and healthy tissues to identify mutations linked to tumor development. This technological advancement is creating a robust framework for developing potent cancer treatments, further driving the growth of the epigenetics market in Europe.
Europe Epigenetics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence and Prevalence of Cancer
-
1.2.2 Increasing Funding for R&D in Healthcare
-
1.2.3 Rising Epigenetic Applications in Non-Oncology Diseases
-
-
1.3 Market Restraints
-
1.3.1 Rising Cost of Instruments
-
1.3.2 Dearth of Skilled Researchers
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product
-
2.1.1 By Kits
-
2.1.1.1 Bisulfite Conversion Kits
-
2.1.1.2 Chip-seq Kits
-
2.1.1.3 RNA Sequencing Market
-
2.1.1.4 Whole Genome Amplification Market
-
2.1.1.5 5-HMC and 5-MC Analysis Kits
-
2.1.1.6 Other Kits
-
-
2.1.2 By Reagents
-
2.1.2.1 Antibodies
-
2.1.2.2 Buffers
-
2.1.2.3 Histones
-
2.1.2.4 Magnetic Beads
-
2.1.2.5 Primers
-
2.1.2.6 Other Reagents
-
-
2.1.3 By Enzymes
-
2.1.3.1 DNA - Modifying Enzymes
-
2.1.3.2 Protein Modifying Enzymes
-
2.1.3.3 RNA Modifying Enzymes
-
-
2.1.4 By Instruments
-
2.1.4.1 Mass Spectrometer
-
2.1.4.2 Sonicators
-
2.1.4.3 Next Generation Sequencers
-
2.1.4.4 Other Instruments
-
-
-
2.2 By Application
-
2.2.1 Oncology
-
2.2.2 Non-Oncology
-
2.2.2.1 Inflammatory Diseases
-
2.2.2.2 Metabolic Diseases
-
2.2.2.3 Infectious Diseases
-
2.2.2.4 Cardiovascular Diseases
-
2.2.2.5 Other Non-Oncology Applications
-
-
2.2.3 Developmental Biology
-
2.2.4 Other Research Areas
-
-
2.3 By Technology
-
2.3.1 DNA Methylation
-
2.3.2 Histone Methylation
-
2.3.3 Histone Acetylation
-
2.3.4 Large noncoding RNA
-
2.3.5 MicroRNA modification
-
2.3.6 Chromatin Structures
-
-
2.4 Geography
-
2.4.1 Europe
-
2.4.1.1 Germany
-
2.4.1.2 UK
-
2.4.1.3 France
-
2.4.1.4 Italy
-
2.4.1.5 Spain
-
2.4.1.6 Rest of Europe
-
-
-
Europe Epigenetics Market Size FAQs
What is the current Europe Epigenetics Market size?
The Europe Epigenetics Market is projected to register a CAGR of 14.5% during the forecast period (2024-2029)
Who are the key players in Europe Epigenetics Market?
Illumina Inc., Merck & Co. Inc., QIAGEN, Thermo Fisher Scientific and Zymo Research Corporation are the major companies operating in the Europe Epigenetics Market.
